Researchers at the University of Barcelona have identified a promising combination therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) using two existing drugs: pemafibrate, a lipid-lowering agent, and telmisartan, an antihypertensive medication. In animal models, this combination not only significantly reduced liver fat but also showed potential to mitigate cardiovascular risks associated with the disease. Notably, the study demonstrated that lower doses of both drugs were as effective as higher doses of either drug used alone, suggesting a synergistic effect that could enhance safety profiles.

The significance of these findings lies in the urgent need for effective treatments for MASLD, which affects approximately one in three adults globally and is a leading cause of liver-related morbidity and mortality. Current treatment options are limited, and many experimental drugs have failed in clinical trials due to safety concerns. By repurposing pemafibrate and telmisartan, both of which have established safety records, this research opens avenues for a safer and more effective therapeutic strategy targeting the early stages of MASLD, potentially preventing progression to more severe liver damage and associated cardiovascular complications.

The implications for the field are substantial, as this study shifts the paradigm towards combination therapies that leverage existing drugs to address complex metabolic disorders. It emphasizes the importance of exploring drug repurposing strategies, which could accelerate the development of effective treatments while minimizing risks. Future clinical studies will be essential to validate these findings in human subjects and to explore the efficacy of this combination in more advanced stages of MASLD, particularly in patients with liver fibrosis and cardiovascular disease.

Source: sciencedaily.com